{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:02:48Z","timestamp":1793318568988,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T00:00:00Z","timestamp":1483574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10067-016-3528-y","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T01:35:13Z","timestamp":1483580113000},"page":"753-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry"],"prefix":"10.1007","volume":"36","author":[{"given":"Sara","family":"Monti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pellerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Andrea","family":"Rocchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio Giulio","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"issue":"3","key":"3528_CR1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C et al (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516\u2013528","journal-title":"Ann Rheum Dis"},{"key":"3528_CR2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86\u201394","journal-title":"Ann Rheum Dis"},{"key":"3528_CR3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jbspin.2012.09.023","volume":"80","author":"A Pierreisnard","year":"2013","unstructured":"Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T (2013) Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Jt Bone Spine Rev Rhum 80:386\u2013392","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"3528_CR4","doi-asserted-by":"crossref","first-page":"831603","DOI":"10.1155\/2014\/831603","volume":"2014","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Bugatti S, Biggioggero M, Caporali R (2014) Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int 2014:831603","journal-title":"Biomed Res Int"},{"key":"3528_CR5","doi-asserted-by":"crossref","unstructured":"Jobanputra P, Maggs F, Deeming A, et al. (2012) A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2\u00a0years. BMJ Open 2(6)","DOI":"10.1136\/bmjopen-2012-001395"},{"issue":"9877","key":"3528_CR6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877):1541\u20131550","journal-title":"Lancet"},{"key":"3528_CR7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492\u2013509","journal-title":"Ann Rheum Dis"},{"key":"3528_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2009.12.010","volume":"9","author":"R Caporali","year":"2010","unstructured":"Caporali R, Sarzi-Puttini P, Atzeni F et al (2010) Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 9:465\u2013469","journal-title":"Autoimmun Rev"},{"key":"3528_CR9","unstructured":"Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol"},{"key":"3528_CR10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/14397595.2013.872862","volume":"24","author":"Y Tanaka","year":"2014","unstructured":"Tanaka Y, Kubo S, Yamanaka H et al (2014) Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia\u00ae as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol 24:754\u2013762","journal-title":"Mod Rheumatol"},{"key":"3528_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Xie F, Delzell E, Levitan EB et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol Hoboken NJ 68:56\u201366","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"3528_CR12","doi-asserted-by":"crossref","unstructured":"Cantini F, Niccoli L, Nannini C, et al. (2015) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum","DOI":"10.1016\/j.semarthrit.2015.10.001"},{"key":"3528_CR13","first-page":"290","volume":"60","author":"P Sarzi-Puttini","year":"2008","unstructured":"Sarzi-Puttini P, Antivalle M, Marchesoni A et al (2008) Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:290\u2013295","journal-title":"Reumatismo"},{"issue":"4 Suppl 73","key":"3528_CR14","first-page":"S21","volume":"30","author":"M Broek van den","year":"2012","unstructured":"van den Broek M, Lems WF, Allaart CF (2012) Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 30(4 Suppl 73):S21\u2013S26","journal-title":"Clin Exp Rheumatol"},{"key":"3528_CR15","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.clinthera.2013.10.008","volume":"35","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Hirata S (2013) Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther 35:2028\u20132035","journal-title":"Clin Ther"},{"key":"3528_CR16","unstructured":"Moghadam MG, Vonkeman HE, Ten Klooster PM, et al. (2016) Stopping tumor necrosis factor-inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open-label controlled trial. Arthritis Rheumatol Hoboken NJ"},{"key":"3528_CR17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/kep129","volume":"48","author":"BJ Radovits","year":"2009","unstructured":"Radovits BJ, Fransen J, Eijsbouts A, van Riel PLCM, Laan RFJM (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology 48:906\u2013910","journal-title":"Rheumatology"},{"key":"3528_CR18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-015-0021-z","volume":"2","author":"K Morsley","year":"2015","unstructured":"Morsley K, Kilner T, Steuer A (2015) Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study. Rheumatol Ther 2:165\u2013172","journal-title":"Rheumatol Ther"},{"key":"3528_CR19","first-page":"301","volume":"20","author":"WJ Martin","year":"2014","unstructured":"Martin WJ, Shim M, Paulus HE et al (2014) Older age at rheumatoid arthritis onset and comorbidities correlate with less health assessment questionnaire-disability index and clinical disease activity index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 20:301\u2013305","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"3528_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40266-015-0341-2","volume":"33","author":"T Sugihara","year":"2016","unstructured":"Sugihara T, Harigai M (2016) Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging 33:97\u2013107","journal-title":"Drugs Aging"},{"key":"3528_CR21","doi-asserted-by":"crossref","unstructured":"Zhang J, Xie F, Yun H, et al. (2016) Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2015-207870"},{"key":"3528_CR22","doi-asserted-by":"crossref","first-page":"e0146991","DOI":"10.1371\/journal.pone.0146991","volume":"11","author":"G Crepaldi","year":"2016","unstructured":"Crepaldi G, Scir\u00e8 CA, Carrara G et al (2016) Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoS One 11:e0146991","journal-title":"PLoS One"},{"key":"3528_CR23","first-page":"1511","volume":"28","author":"EJ Kroot","year":"2001","unstructured":"Kroot EJ, van Gestel AM, Swinkels HL, Albers MM, van de Putte LB, van Riel PL (2001) Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 28:1511\u20131517","journal-title":"J Rheumatol"},{"key":"3528_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-016-0928-y","volume":"18","author":"L Innala","year":"2016","unstructured":"Innala L, Sj\u00f6berg C, M\u00f6ller B et al (2016) Co-morbidity in patients with early rheumatoid arthritis - inflammation matters. Arthritis Res Ther 18:33","journal-title":"Arthritis Res Ther"},{"key":"3528_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62\u201368","journal-title":"Ann Rheum Dis"},{"key":"3528_CR26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X15612250","volume":"7","author":"K Iqbal","year":"2015","unstructured":"Iqbal K, Kelly C (2015) Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 7:247\u2013267","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3528_CR27","doi-asserted-by":"crossref","first-page":"759760","DOI":"10.1155\/2013\/759760","volume":"2013","author":"L Cavagna","year":"2013","unstructured":"Cavagna L, Monti S, Grosso V et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760","journal-title":"Biomed Res Int"},{"key":"3528_CR28","doi-asserted-by":"crossref","unstructured":"Marino S, Sud D, Plessner H, et al. (2007) Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol [Internet] 3(10)","DOI":"10.1371\/journal.pcbi.0030194"},{"key":"3528_CR29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","volume":"66","author":"R Alten","year":"2014","unstructured":"Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC (2014) Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol Hoboken NJ 66:1987\u20131997","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"3528_CR30","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096\u20131103","journal-title":"Ann Rheum Dis"},{"key":"3528_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25\u201332","journal-title":"Ann Rheum Dis"},{"key":"3528_CR32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88\u201396","journal-title":"Ann Rheum Dis"},{"key":"3528_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.18553\/jmcp.2015.21.5.409","volume":"21","author":"F Buckley","year":"2015","unstructured":"Buckley F, Finckh A, Huizinga TWJ, Dejonckheere F, Jansen JP (2015) Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21:409\u2013423","journal-title":"J Manag Care Spec Pharm"},{"key":"3528_CR34","doi-asserted-by":"crossref","unstructured":"Gabay C, Riek M, Hetland ML, et al. (2015) Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2015-207760"},{"key":"3528_CR35","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatol Oxf Engl 53:1664\u20131668","journal-title":"Rheumatol Oxf Engl"},{"key":"3528_CR36","doi-asserted-by":"crossref","unstructured":"Lee YH, Bae S-C (2015) Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis","DOI":"10.1111\/1756-185X.12822"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3528-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:59:05Z","timestamp":1568681945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3528-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3528"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3528-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]}}}